SK Biopharmaceuticals’ new epilepsy drug increases expectation for US FDA approval

A SK Biopharmaceuticals’ new epilepsy drug has been increasingly expected to acquire immediate approval from the U.S. FDA.

According to the industry concerned on the 15^th, ‘YKP3089,’ a new epilepsy drug that is being developed by SK Biopharmaceuticals, a subsidiary of SK Group, has a high chance to acquire approval through its recognition in safety tests from the U.S. FDA.

Then, the Phase 3...